

Over 108 million people in India suffer from endocrine and metabolic disorders. Diabetes is the most prevalent disease in this therapeutic area with approximately 63 million cases in 2013. Our Principal Investigators see 400 - 500 new cases per month, and approximately 2000 recurrent cases per month.

As diabetes becomes a potential epidemic in India, this figure is likely to rise to 80 million by 2025 and by 2030, it is expected to cross the 100 million mark (one in every 10 adults), near twice as many as expected in China.

In 2011, nearly 983, 000 deaths were reported to be caused due to diabetes, thereby making it the largest contributor to mortality. Seventy eight thousand children are reported to develop type1 diabetes, every year. In other metabolic centric disease, 42 million people in India suffer from thyroid diseases.


A 2013 World Bank estimate reports that since the year 2000, there has been a steady, 17% decline in fertility. Out of every 100 couples in India who visit the infertility clinics, the female is infertile in 50% of cases and the male, in 40%.

### Our Sites and Investigators

Our access to the most prominent endocrinology sites and investigators ensures a large and diverse patient pool along with the most up-to-date lines of medical treatment. We ensure that clinical trials are conducted according to ICH-GCP guidelines and meet the highest standards of ethics and integrity.

Common metabolic centric diseases also seen in India are thyroid, reproductive/fertility, obesity, lipid disorders, and growth disorders.

CITIES	SITES	INVESTIGATORS
Mumbai	11	20
Delhi/ NCR	10	20
Chennai	10	18
Kolkata	9	15
Bangalore	9	15
Hyderabad	7	12
Ahmedabad	7	10
Pune	5	12
Jaipur	5	8
Nagpur	4	5
Others	26	53
<b>Total</b>	<b>103</b>	<b>188</b>



### Excel Life Sciences Endocrinology Experience

INDICATION	PHASE	SUBJECTS ENROLLED	TIME (MO.)
Diabetes Mellitus	II	143	16
Diabetes Mellitus	III	369	9
Diabetes	III	100	7
Diabetes	III	78	4
Diabetes Macular Edema	III	40	2
Diabetes	III	21	1

Excel Life Sciences (ELS) is India's premier clinical trial and site management organization with extensive regulatory and clinical trials expertise. ELS has conducted over 40 studies for FDA submission and has undergone successful FDA and EMEA audits. We lead a network of ICH-GCP compliant investigators across 30 cities. Excel Life Sciences has offices in Boston, Chicago, New Delhi, and Research Triangle Park, NC.

USA +1 – 877 – EXCELOK (877) 392 – 3565 INDIA +91 120 4022 600

E-MAIL [excel@excellifesciences.com](mailto:excel@excellifesciences.com) WEB SITE [www.excellifesciences.com](http://www.excellifesciences.com)